NCT06856187View on ClinicalTrials.gov

Second-line Standard Treatment Sequential TAS-102 and Bevacizumab Combined With Local Treatment in Advanced Colorectal Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

119

Participants

Timeline

Start Date

February 28, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

April 30, 2027

Conditions
Metastatic Colorectal Cancer (CRC)
Interventions
DRUG

TAS-102+bevacizumab+local treatment

patients achieve disease control after second-line induction therapy with standard therapy(FOLFOX/FOLFIRI/XELOX/ mXELIRI＋bevacizumab/cetuximab), then achieve TAS-102+bevacizumab+local treatment

DRUG

Standard chemotherapy

Standard therapy：FOLFOX/FOLFIRI/XELOX/ mXELIRI±bevacizumab/cetuximab

Trial Locations (1)

200032

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER